Skip to content
Clinical Trials – home
LatviaBack to Latvia

Clinical trials in Sigulda – page 8

116 clinical trials in Sigulda, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Sigulda at a glance
116
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

116 trials in Sigulda

Open in trial search

Study of Efgartigimod PH20 SC for Adults with Thyroid Eye Disease

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Hypertriglyceridaemia

Not recruiting

Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Pemphigoid

Not recruiting

Study on Efgartigimod Alfa and Prednisone for Adults with Bullous Pemphigoid

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Colitis ulcerative

Not recruiting

Study on Rifamycin SV for Patients with Mild to Moderate Left-Sided Ulcerative Colitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Rifamycin Sodium
  • Sponsor:Cosmo Technologies Limited

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Cilastatin
  • Sponsor:Spero Therapeutics Inc.

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine
  • Sponsor:Cardurion Pharmaceuticals Inc.

Study of Danicopan for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Embolism

Not recruiting

Study on REGN7508 for Preventing Blood Clots in Adults After Knee Replacement Surgery

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:Regeneron Pharmaceuticals Inc.

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Gliclazide MR, Dapagliflozin, and Metformin for Patients with Type 2 Diabetes Not Well Controlled with Dapagliflozin

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Other cities in Latvia

The busiest research cities in the country

All 18 cities in Latvia

Clinical research in Sigulda

What the registry says about research in the country

01 Diabetes Research

Clinical investigations focusing on advancing treatment options for patients with Type 2 Diabetes who aren't achieving optimal control with current medications.

  • Therapeutic Focus: Blood glucose management
  • Treatment Combination Studies
  • Metabolic Disease Research

The research evaluates the effectiveness of combining gliclazide MR with existing diabetes medications to improve glycemic control, particularly focusing on HbA1c reduction in patients with inadequate response to current treatments.

02 Metabolic Disorders

Innovative research exploring combination therapy approaches in metabolic disease management, specifically targeting patients with suboptimal response to standard treatments.

  • Medication Optimization
  • Glycemic Control Studies
  • Treatment Enhancement Research

This clinical investigation aims to advance our understanding of treatment optimization for patients requiring additional therapeutic support beyond initial medication regimens.

03 Treatment Efficacy

Comprehensive evaluation of treatment effectiveness in diabetes management, focusing on medication combinations to achieve better patient outcomes.

  • Safety Assessment
  • Clinical Response Monitoring
  • Long-term Effectiveness

The research examines both the efficacy and safety profiles of combined therapeutic approaches over a 24-week period, providing valuable insights into treatment optimization strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.